Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Public ClinicalTrials.gov record NCT04913337. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study identification
- NCT ID
- NCT04913337
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Enrollment
- 179 participants
Conditions and interventions
Conditions
Interventions
- NGM707 Drug
- NGM707 plus pembrolizumab (KEYTRUDA®) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2021
- Primary completion
- Jan 31, 2025
- Completion
- Jun 30, 2025
- Last update posted
- Oct 1, 2024
2021 – 2025
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NGM Clinical Study Site | Los Angeles | California | 90033 | — |
| NGM Clinical Study Site | Newport Beach | California | 92663 | — |
| NGM Clinical Study Site | Santa Monica | California | 90404 | — |
| NGM Clinical Study Site | Santa Rosa | California | 94505 | — |
| NGM Clinical Study Site | Lone Tree | Colorado | 80124 | — |
| NGM Clinical Study Site | Washington D.C. | District of Columbia | 20007 | — |
| NGM Clinical Study Site | Sarasota | Florida | 34232 | — |
| NGM Clinical Study Site | Baltimore | Maryland | 21201 | — |
| NGM Clinical Study Site | Boston | Massachusetts | 02215 | — |
| NGM Clinical Study Site | Grand Rapids | Michigan | 49546 | — |
| NGM Clinical Study Site | Omaha | Nebraska | 68130 | — |
| NGM Clinical Study Site | Albany | New York | 12206 | — |
| NGM Clinical Study Site | Greenville | South Carolina | 29605 | — |
| NGM Clinical Study Site | Dallas | Texas | 75246 | — |
| NGM Clinical Study Site | Dallas | Texas | 78701 | — |
| NGM Clinical Study Site | Houston | Texas | 77030 | — |
| NGM Clinical Study Site | San Antonio | Texas | 78229 | — |
| NGM Clinical Study Site | San Antonio | Texas | 78240 | — |
| NGM Clinical Study Site | Blacksburg | Virginia | 24060 | — |
| NGM Clinical Study Site | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04913337, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2024 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04913337 live on ClinicalTrials.gov.